Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IB/II investigator-initiated single-arm study of Annamycin for third-line treatment of advanced pancreatic cancer

Next Previous
Trial Profile

Phase IB/II investigator-initiated single-arm study of Annamycin for third-line treatment of advanced pancreatic cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naxtarubicin (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use

Most Recent Events

  • 19 Nov 2025 New trial record
  • 23 Oct 2025 According to a Moleculin biotech media release, Moleculin will supply Annamycin and be responsible for submitting and maintaining an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA), and Dr. Alistar of Atlantic Health will be responsible for conducting the Phase 1B/2 study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top